Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C29H40O7 |
Molecular Weight | 500.6237 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(=O)C(C)(C)C
InChI
InChIKey=FAPMGCFSVXGXMO-FHKBAQRKSA-N
InChI=1S/C29H40O7/c1-25(2,3)24(33)34-15-21(32)29-22(35-26(4,5)36-29)13-19-18-9-8-16-12-17(30)10-11-27(16,6)23(18)20(31)14-28(19,29)7/h10-12,18-20,22-23,31H,8-9,13-15H2,1-7H3/t18-,19-,20-,22+,23+,27-,28-,29+/m0/s1
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DESONIDE Approved UseDesonide Ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician. Launch Date1972 |
|||
Primary | DESONIDE Approved UseDesonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date1972 |
|||
Primary | DESONIDE Approved UseDesonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date1972 |
|||
Primary | DESONIDE Approved UseDesonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date1972 |
|||
Primary | DESONIDE Approved UseDesonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date1972 |
Doses
Dose | Population | Adverse events |
---|---|---|
0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.3 |
unhealthy n = 425 Health Status: unhealthy Condition: Atopic dermatitis Population Size: 425 Sources: Page: p.3 |
Disc. AE: Telangiectasia... AEs leading to discontinuation/dose reduction: Telangiectasia Sources: Page: p.3 |
0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: Page: p.1 |
Disc. AE: Cushing's syndrome, Hypothalamic pituitary adrenal axis suppression... AEs leading to discontinuation/dose reduction: Cushing's syndrome Sources: Page: p.1Hypothalamic pituitary adrenal axis suppression Atrophy Striae Irritation skin Acneiform eruption Skin hypopigmentation Allergic contact dermatitis |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Telangiectasia | Disc. AE | 0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.3 |
unhealthy n = 425 Health Status: unhealthy Condition: Atopic dermatitis Population Size: 425 Sources: Page: p.3 |
Acneiform eruption | Disc. AE | 0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: Page: p.1 |
Allergic contact dermatitis | Disc. AE | 0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: Page: p.1 |
Atrophy | Disc. AE | 0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: Page: p.1 |
Cushing's syndrome | Disc. AE | 0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: Page: p.1 |
Hypothalamic pituitary adrenal axis suppression | Disc. AE | 0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: Page: p.1 |
Irritation skin | Disc. AE | 0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: Page: p.1 |
Skin hypopigmentation | Disc. AE | 0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: Page: p.1 |
Striae | Disc. AE | 0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: Page: p.1 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 4,8 |
yes | yes (co-administration study) Comment: Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide. If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered Page: 4,8 |
PubMed
Title | Date | PubMed |
---|---|---|
Clinical comparison of alclometasone dipropionate and desonide ointments (0.05%) in the management of psoriasis. | 1982 |
|
Allergic contact dermatitis from topical corticosteroids. | 1989 Aug |
|
Two case reports of cutaneous adverse reactions following hepatitis B vaccine: lichen planus and granuloma annulare. | 2004 Sep |
|
[Connubial contact dermatitis to an inhaled corticosteroid]. | 2005 Feb |
|
Erythematous scaling eyelids: patient history, exposure to allergens and irritants are keys to diagnosis. | 2005 Jun |
|
Rapid resolution of a common problem. | 2005 May |
|
Photochemistry of desonide, a non-fluorinated steroidal anti-inflammatory drug. | 2006 Jun |
|
Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. | 2007 Feb |
|
Tega-dermabrasion. | 2007 Sep |
|
Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome. | 2008 Aug |
|
What's your assessment? Severe seborrheic dermatitis. | 2008 Dec |
|
Desonide: a review of formulations, efficacy and safety. | 2008 Jul |
|
A simple and rapid ESI-LC-MS/MS method for simultaneous screening of doping agents in urine samples. | 2009 Apr |
|
Fixed drug eruption induced by atenolol. | 2009 Apr 24 |
|
Inflammation of actinic keratosis with combination of alkylating and taxane agents: a case report. | 2009 Jul 2 |
|
Manifestations of cutaneous sarcoidosis: a case report of an African American woman. | 2009 Jun |
|
Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
|
Vitiligo after diphencyprone for alopecia areata. | 2010 |
|
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. | 2010 Apr |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000034982
Created by
admin on Sat Dec 16 10:07:00 GMT 2023 , Edited by admin on Sat Dec 16 10:07:00 GMT 2023
|
PRIMARY | |||
|
UB3LO24HGK
Created by
admin on Sat Dec 16 10:07:00 GMT 2023 , Edited by admin on Sat Dec 16 10:07:00 GMT 2023
|
PRIMARY | |||
|
DTXSID00229315
Created by
admin on Sat Dec 16 10:07:00 GMT 2023 , Edited by admin on Sat Dec 16 10:07:00 GMT 2023
|
PRIMARY | |||
|
71300443
Created by
admin on Sat Dec 16 10:07:00 GMT 2023 , Edited by admin on Sat Dec 16 10:07:00 GMT 2023
|
PRIMARY | |||
|
78806-68-5
Created by
admin on Sat Dec 16 10:07:00 GMT 2023 , Edited by admin on Sat Dec 16 10:07:00 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD